08:07:09 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2025-02-19 Bokslutskommuniké 2024
2024-11-13 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-30 Split BGBIO 100:1
2024-05-29 Kvartalsrapport 2024-Q1
2024-05-24 X-dag ordinarie utdelning BGBIO 0.00 NOK
2024-05-23 Årsstämma 2024
2024-02-14 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-06-22 Kvartalsrapport 2023-Q1
2023-05-22 Årsstämma 2023
2023-04-21 X-dag ordinarie utdelning BGBIO 0.00 NOK
2023-02-16 Bokslutskommuniké 2022
2022-11-15 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-04-29 X-dag ordinarie utdelning BGBIO 0.00 NOK
2022-04-28 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2022-01-06 Extra Bolagsstämma 2022
2021-11-16 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-19 Kvartalsrapport 2021-Q1
2021-03-22 X-dag ordinarie utdelning BGBIO 0.00 NOK
2021-03-19 Årsstämma 2021
2021-02-10 Bokslutskommuniké 2020
2020-12-09 Extra Bolagsstämma 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-19 Kvartalsrapport 2020-Q1
2020-03-17 X-dag ordinarie utdelning BGBIO 0.00 NOK
2020-03-16 Årsstämma 2020
2020-02-11 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-19 Kvartalsrapport 2019-Q2
2019-05-08 Kvartalsrapport 2019-Q1
2019-03-14 X-dag ordinarie utdelning BGBIO 0.00 NOK
2019-03-13 Årsstämma 2019
2019-02-19 Bokslutskommuniké 2018
2018-11-13 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-05-15 X-dag ordinarie utdelning BGBIO 0.00 NOK
2018-05-15 Kvartalsrapport 2018-Q1
2018-05-14 Årsstämma 2018
2018-03-09 Extra Bolagsstämma 2018
2018-02-13 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-18 Kvartalsrapport 2017-Q2
2017-05-23 Kvartalsrapport 2017-Q1
2017-03-23 X-dag ordinarie utdelning BGBIO 0.00 NOK
2017-03-22 Årsstämma 2017
2016-06-22 X-dag ordinarie utdelning BGBIO 0.00 NOK
2016-06-21 Årsstämma 2016
2015-06-23 X-dag ordinarie utdelning BGBIO 0.00 NOK
2015-06-22 Årsstämma 2015


ListaOB Match
BerGenBio är ett norskt onkologibolag. Idag bedriver bolaget forskning och utveckling av hämmande läkemedel för behandling av aggressiva cancertyper. Bolaget har utvecklat ett flertal produkter vars sammansättning ämnar blockera proteinet AXL, ett protein positivt relaterat med spridning av cancercellerna. Bolaget grundades under 2007 och har sitt huvudkontor i Bergen, Norge.
2023-03-28 08:00:00

- Data on AXL as a therapeutic target in lung cancers to be highlighted at AACR -

- Ph1a/2b 1L STK11m NSCLC trial design to be outlined at ELCC -

BERGEN, Norway, March 28,2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that the Company will be presenting three posters at two upcoming scientific conferences: ESMO's European Lung Cancer Congress (ELCC) 2023 and the American Association for Cancer Research (AACR) Annual Meeting 2023.

European Lung Cancer Conference 2023

March 29 - April 1, 2023

Bella Center - Copenhagen, Denmark

Poster Title: Phase 1b/2a safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous NSCLC with/without STK11 mutations (https://cslide.ctimeetingtech.com/elcc23hybrid/attendee/confcal/presentation/list?q=78TiP)

Session Title: Poster Display session (ID 51)

Session Date & Time: Friday March 31, 2023, 12:00 PM - 12:45 PM

Location: Exhibition and Poster area

Presentation Number: 78TiP

American Association for Cancer Research Annual Meeting 2023

April 14 - 19, 2023

Orlando County Convention Center - Orlando, Florida

Poster Title: AXL as a Therapeutic Target in STK11 mutant NSCL (https://www.abstractsonline.com/pp8/#!/10828/presentation/3138)C 
Session Title: Combination Immunotherapies 1 
Session Date and Time: Monday Apr 17, 2023, 1:30 PM - 5:00 PM 
Location: Section 39 
Poster Board Number: 18 
Abstract Presentation Number: 3245 

Poster Title:  Combined inhibition of AXL and ATR enhances replication stress, cell death and immune response in small cell lung cancer (https://www.abstractsonline.com/pp8/#!/10828/presentation/1853
Session Title:  DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes 
Session Date and Time: Wednesday Apr 19, 2023, 9:00 AM - 12:30 PM 
Location: Section 18 
Poster Board Number: 8 
Abstract Presentation Number: 6206 

The posters from both conferences will be available on the Company's website in the Scientific Presentations (https://www.bergenbio.com/investors/presentations/) portion of the Investors section following their presentations.



Martin Olin CEO, BerGenBio ASA 


Rune Skeie, CFO, BerGenBio ASA 


Investor Relations / Media Relations 

Graham Morrell 


Media Relations Norway

Jan Lilleby


+47 90 55 16 98

About BerGenBio ASA 

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and COVID-19. 

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com  

Forward looking statements 

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.